Provided by Tiger Trade Technology Pte. Ltd.

HUTCHMED

23.000
+0.7003.14%
Volume:9.85M
Turnover:226.79M
Market Cap:20.06B
PE:44.23
High:23.560
Open:22.220
Low:21.960
Close:22.300
52wk High:26.000
52wk Low:15.570
Shares:872.00M
HK Float Shares:872.00M
Volume Ratio:2.21
T/O Rate:1.13%
Dividend:- -
Dividend Rate:- -
EPS(LYR):0.520
ROE:1.46%
ROA:-1.24%
PB:2.03
PE(LYR):44.23
PS:4.65

Loading ...

Major Drugmakers Turn to China for Licensing Deals

Reuters
·
Yesterday

Movement Alert|HUTCHMED Rises 5.11% in Regular Trading, AstraZeneca Submits US NDA for Lung Cancer Combination Therapy

Market Focus
·
Yesterday

HUTCHMED Shares Rise Over 3% After Announcing FDA Submission for Orpathys and Tagrisso Combination Therapy

Stock News
·
Yesterday

UK's Billington Holdings H1 Profit Jumps 70% on Data Centre Demand

Reuters
·
Sep 29

UK Stocks-Factors to Watch on September 29

Reuters
·
Sep 29

China's Hutchmed Climbs as AstraZeneca Applies for US Cancer Drug Approval

Reuters
·
Sep 29

Hutchmed (China) Says Astrazeneca Submits US NDA for Orpathys Plus Tagrisso

Reuters
·
Sep 29

HUTCHMED Announces U.S. New Drug Application Submission for ORPATHYS® Combined with TAGRISSO® in MET-Driven EGFR-Mutant Lung Cancer

Stock News
·
Sep 29

Hutchmed Says AstraZeneca Files US NDA for Orpathys-Tagrisso Lung Cancer Combo

Reuters
·
Sep 29

Hutchmed Announces Submission of US Nda for Orpathys® Plus Tagrisso® in Met-Driven Egfr-Mutated Lung Cancer

THOMSON REUTERS
·
Sep 29

Hutchmed Climbs After on Initiating HMPL-A830 Global Trial in Solid Tumors

Reuters
·
Sep 28

HUTCHMED Launches First-in-Human Global Phase I Trial for KRAS-EGFR Antibody-Targeted Therapy HMPL-A830

Bulletin Express
·
Sep 28

HUTCHMED Launches Global Phase I Study of KRAS-EGFR Antibody-Targeted Therapy HMPL-A830 for Solid Tumors

Stock News
·
Sep 28

Hutchmed Initiates Global Trial of Kras-Egfr-Antibody Conjugate Therapy Hmpl-A830 in Patients with Solid Tumors

THOMSON REUTERS
·
Sep 28

HUTCHMED Initiates Global Trial of KRAS-EGFR-Antibody Conjugate Therapy HMPL-A830 in Patients with Solid Tumors

GlobeNewswire
·
Sep 28

HUTCHMED to Showcase Positive Phase III Data on Savolitinib–Osimertinib Combination at ESMO 2026

Bulletin Express
·
Sep 24

Hutchmed Says Saffron Phase III Trial of Savolitinib-Osimertinib Combo Beats Chemo in EGFR-Mutant NSCLC After Osimertinib Progression

Reuters
·
Sep 24

BofA Adjusts Price Target on HUTCHMED (China) to $18 From $16, Keeps Buy Rating

MT Newswires Live
·
Sep 21

Market Chatter: US Considers Rules Allowing American Investment in Chinese Drugs

MT Newswires Live
·
Sep 21

HUTCHMED Surges in Late Hong Kong Trading as GSK Licensing Deal Signals Clear Global Expansion Path

Stock News
·
Sep 17